Date: 12th November, 2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Submission of Press Release pertaining to Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Press Release pertaining to the announcement of Unaudited financial results for the Quarter and Half Year ended 30th September, 2026, for your information.

The same will also be available on the Company's website at www.balaxipharma.in

We request you to kindly take the same on record and treat this submission as compliance with the applicable provisions of the SEBI Listing Regulations.

Thanking You.

Yours faithfully,
For Balaxi Pharmaceuticals Limited

AMAN PUROHIT
Digitally signed by AMAN PUROHIT
Date: 2026.11.12 20:26:23 +05'30'


Aman Purohit
(Company Secretary & Compliance Officer)
ICSI Membership No.: A59345


(Encl: As above)


Balaxi Pharmaceuticals Limited Reports Strong Q2 FY27 Performance; Revenue Grows 45%, EBITDA Surges 338% and PAT Rises 450% YoY

Hyderabad, November 12, 2026: Balaxi Pharmaceuticals Limited, a branded, IPR-driven pharmaceutical company with an established presence across frontier and semi-regulated markets in Africa and Latin America, today announced its unaudited financial results for the second quarter (Q2 FY27) and half year (H1 FY27) ended September 30, 2026.

Q2 &H1 FY27 FINANCIAL HIGHLIGHTS (Consolidated)







Particulars (In ₹ Lakh)	Q2 FY27	Q2 FY26	YoY Change	H1 FY27	H1 FY26	YoY Change
Revenue from Operations	**8,137.23**	5,617.53	↑ 44.85%	**16,205.40**	12,691.74	↑ 27.68%
EBITDA	**512.07**	116.86	↑ 338.19%	**978.31**	531.71	↑ 83.99%
EBITDA Margin (%)	**6.29%**	2.08%	↑ 421 BPS	**6.04%**	4.19%	↑ 185 BPS
Profit After Tax (PAT)	**115.01**	20.90	↑450.29%	**244.76**	49.92	↑390.30%
PAT Margin (%)	**1.41%**	0.37%	↑ 104 BPS	**1.51%**	0.39%	↑ 112 BPS
Diluted EPS (₹)	**0.21**	0.04	↑425.00%	**0.44**	0.09	↑388.89%

MANAGEMENT COMMENTARY

Commenting on the result, Mr. Ashish Maheshwari, Chairman & Managing Director, said:

"The pharmaceutical markets across Africa and Latin America continue to offer opportunities for companies with established distribution networks, local market understanding and a diversified portfolio of affordable medicines. At Balaxi Pharmaceuticals, we remain focused on strengthening our presence across these markets through our branded, IPR-driven business model.

Over the years, we have developed a strong foundation supported by an extensive product registration portfolio, local warehousing infrastructure and an established distribution network. During H1 FY27, we added 31 new product registrations, further strengthening our ability to introduce products and address evolving therapeutic requirements across our operating markets.

Latin America remains an important part of our growth strategy, with continued focus on Guatemala, Dominican Republic, Honduras and El Salvador. At the same time, we are working towards improving operating efficiencies and cash conversion in Angola.

With our Jadcherla manufacturing facility now operational, we are entering the next phase of our business development, where in-house manufacturing, branded generics and geographical expansion will remain our key priorities. We aim to leverage these capabilities to strengthen our competitive position and participate in the growing demand for affordable pharmaceutical products across frontier and semi-regulated markets."

ABOUT BALAXI PHARMACEUTICALS LTD

Balaxi Pharmaceuticals Limited is a branded, IPR-driven pharmaceutical company focused on serving frontier and semi-regulated markets across Africa and Latin America. With over two decades of experience, the Company has established a presence across international markets through its extensive product registration portfolio, warehousing infrastructure and distribution network. Its business model encompasses market research, product selection, regulatory registrations, sourcing, manufacturing and distribution of essential medicines, generics and branded generics.

The Company operates through an established network of 38 warehouses, supported by over 500 professionals, including 80+ expatriate managers, and has 1,001 registered products across its portfolio. Balaxi has strengthened its manufacturing capabilities with the commencement of operations at its own oral solid dosage formulation facility at Jadcherla, Telangana, designed to manufacture tablets and capsules. With a focus on manufacturing integration, expansion of branded generics and deeper penetration into existing and new markets, the Company aims to strengthen its position in the global pharmaceutical supply chain.

DISCLAIMER

This document contains forward-looking statements, which are not historical facts and are subject to risks and uncertainties such as government actions, local developments, and technological risks. The Company is not responsible for any actions taken based on these statements and does not commit to publicly updating them to reflect future events or circumstances.

INVESTOR RELATIONS PARTNER

ORIM CONNECT
+(91) 82085 63201
letsconnect@orim.in
www.orim.in/orim-connect/